Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Declines By 78.7%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 13,319 shares, a decrease of 78.7% from the April 15th total of 62,619 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 42,961 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. SmartHarvest Portfolios LLC acquired a new position in Genenta Science during the fourth quarter worth $26,000. Citadel Advisors LLC acquired a new position in Genenta Science during the third quarter worth $41,000. Alyeska Investment Group L.P. acquired a new position in Genenta Science during the fourth quarter worth $328,000. Norges Bank acquired a new stake in shares of Genenta Science during the fourth quarter worth about $337,000. Finally, Weiss Asset Management LP acquired a new stake in shares of Genenta Science during the fourth quarter worth about $480,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genenta Science in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Genenta Science Price Performance

GNTA stock traded down $0.00 during trading on Friday, hitting $0.63. The stock had a trading volume of 17,437 shares, compared to its average volume of 721,182. Genenta Science has a twelve month low of $0.55 and a twelve month high of $10.00. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. The company’s 50-day moving average price is $0.72 and its two-hundred day moving average price is $1.26.

Genenta Science (NASDAQ:GNTA) last issued its earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.28.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.